{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
XOMA Corp. Hits New 52-Week High, Surging 70.55% This Year
XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 39.92 on October 3, 2025, reflecting a one-year gain of 70.55%. The company, with a market cap of USD 427 million, remains loss-making and does not offer dividends.
XOMA Corp. Hits New 52-Week High of $39.33, Up 68.44%
XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 39.33 on October 1, 2025, reflecting a 68.44% increase from its low. With a market cap of USD 427 million, the company faces challenges in profitability but remains focused on growth.
XOMA Corp. Hits New 52-Week High of $38.60, Surging 65.48%
XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.60 on September 30, 2025, reflecting a 65.48% increase from its low. The company has a market cap of USD 427 million and faces challenges with a negative return on equity.
XOMA Corp. Hits New 52-Week High of $38.48, Reflecting Strong Growth
XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.48 on September 23, 2025, reflecting a 61.44% increase from its low. With a market cap of USD 427 million, the company has a manageable debt-to-equity ratio but is currently loss-making.
Is XOMA Corp. technically bullish or bearish?
As of August 12, 2025, XOMA Corp. has a bullish technical trend supported by strong indicators, outperforming the S&P 500 with a year-to-date return of 43.04% compared to 12.22%.
Is XOMA Corp. overvalued or undervalued?
As of March 9, 2023, XOMA Corp.'s valuation has shifted from attractive to risky due to overvaluation indicated by high Price to Book and negative EV ratios, despite strong year-to-date and three-year returns compared to the S&P 500, suggesting caution for potential investors.
XOMA Corp. Hits New 52-Week High of $38.45, Up 61.4%
XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.45 on September 18, 2025, reflecting a 61.4% increase from its low. With a market cap of USD 427 million, the company remains unprofitable but maintains a low debt-to-equity ratio.
XOMA Corp. Hits New 52-Week High of $38.34, Reflecting Strong Growth
XOMA Corp., a microcap in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 38.34 on September 16, 2025, reflecting a 59.25% increase from its low. The company has a market cap of USD 427 million and is currently operating at a loss, with a debt-to-equity ratio of 0.33.
Is XOMA Corp. overvalued or undervalued?
As of March 9, 2023, XOMA Corp. is considered overvalued and risky, with concerning financial ratios, including a Price to Book Value of 3.57 and a negative P/E ratio of -29.55, indicating challenges in profitability compared to its peers.
Is XOMA Corp. technically bullish or bearish?
As of May 27, 2025, XOMA Corp. shows a mildly bearish trend overall, influenced by daily moving averages and a bearish monthly MACD, despite some bullish signals from Bollinger Bands and the weekly KST.
Who are in the management team of XOMA Corp.?
As of March 2022, the management team of XOMA Corp. includes Mr. W. Denman Van Ness (Independent Chairman), Mr. James Neal (CEO), and several independent directors: Ms. Natasha Hernday, Ms. Barbara Kosacz, Mr. Joseph Limber, Mr. Matthew Perry, and Mr. Jack Wyszomierski. This team combines independent oversight with executive leadership for effective governance.
What does XOMA Corp. do?
XOMA Corp. is a micro-cap biotechnology company focused on developing monoclonal antibody-based therapeutics. As of March 2025, it reported net sales of $16 million and a net profit of $2 million.
How big is XOMA Corp.?
As of Jun 18, XOMA Corp. has a market capitalization of 286.37 million, with net sales of 42.91 million and a net profit of -2.86 million over the last four quarters. As of Dec 24, shareholder's funds are 81.92 million and total assets are 226.96 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
